Daiichi Sankyo Company, Limited (TYO:4568)
Japan
· Delayed Price · Currency is JPY 3,456.00
-116.00 (-3.25%)
At close: Dec 5, 2025
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 500.76B JPY in the quarter ending September 30, 2025, with 12.14% growth. This brings the company's revenue in the last twelve months to 1.98T, up 12.56% year-over-year. In the fiscal year ending March 31, 2025, Daiichi Sankyo Company had annual revenue of 1.89T with 17.77% growth.
Revenue (ttm)
1,978.88B
Revenue Growth
+12.56%
P/S Ratio
3.23
Revenue / Employee
100.12M
Employees
19,765
Market Cap
6,397.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1,886.26B | 284.57B | 17.77% |
| Mar 31, 2024 | 1,601.69B | 323.21B | 25.28% |
| Mar 31, 2023 | 1,278.48B | 233.59B | 22.36% |
| Mar 31, 2022 | 1,044.89B | 82.38B | 8.56% |
| Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,213.71B |
| HOYA Corporation | 892.50B |
| Takeda Pharmaceutical Company | 4,417.00B |
| Otsuka Holdings | 2,418.53B |
| Astellas Pharma | 2,006.82B |
| Terumo | 1,062.42B |
| Shionogi & | 437.26B |
| Olympus | 977.65B |
Daiichi Sankyo Company News
- 3 days ago - Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen - Business Wire
- 23 days ago - Daiichi Sankyo partnering with General Proximity on oncology targets - Seeking Alpha
- 23 days ago - General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC™ Platform - PRNewsWire
- 26 days ago - DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo - Business Wire
- 4 weeks ago - Daiichi Sankyo Company, Limited (DSNKY) Q2 FY2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Q2 2026 Daiichi Sankyo Co Ltd Earnings Presentation Transcript - GuruFocus
- 5 weeks ago - Daiichi Sankyo (DSKYF) Reports Strong 1H Financial Results - GuruFocus
- 5 weeks ago - Daiichi Sankyo GAAP EPS of ¥70.52, revenue of ¥975.35B; updates FY outlook - Seeking Alpha